ATC code None Synonyms GFT505, SureCN815512 PubChem CID 9864881 Molar mass 384.489 g/mol | Legal status Investigational CAS Number 923978-27-2 ChemSpider 8040573 | |
 | ||
Elafibranor (INN, code name GFT505) is an experimental medication that is being studied and developed by Genfit for the treatment of cardiometabolic diseases including diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).
Contents
Elafibranor is a dual PPARα/δ agonist.
Clinical studies
Administered to over 800 patients and healthy volunteers to date, elafibranor has demonstrated:
Phase 2b (GOLDEN) results were published online in Gastroenterology in February 2016 and will be fully available in the paper version in May 2016.
As of February 2016, elafibranor has completed 8 clinical trials and a phase III is in progress.
Pre-clinical studies
Efficacy on histological NASH parameters (steatosis, inflammation, fibrosis) in animal disease models — anti-fibrotic activities.
The absence of safety concern has been confirmed in a full toxicological package up to 2-year carcinogenicity studies and cardiac studies (in mice).